In a long-awaited pronouncement from the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group, 1 year study results have shown that the monthly use of either Avastin (bevacizumab) or Lucentis (ranibizumab) result in the same visual acuity outcome. The results will come as little or no surprise to the vast majority of clinical ophthalmologists in both the US and the EU.